AbbVie announced that the US FDA has approved aztreonam and avibactam (Emblaveo), in combination with metronidazole, for ...

Ten months after Pfizer scored approval in Europe for Emblaveo (aztreonam and avibactam) to treat complicated intra-abdominal infections (cIAIs), AbbVie has done the same in the U.S., ...

The FDA has approved Emblaveo with metronidazole for patients with complicated intra-abdominal infections and limited options.

The injectable antibiotic can also used for cIAI caused by all those organisms, plus seven Bacteroides strains, Citrobacter freundii, Fusobacterium nucleatum, Klebsiella oxytoca and ...

It's the first and only such therapy approved to fight antimicrobial resistance, or AMR, in bacterial infections.

"Antibiotics reduce the diversity of the ... the greater the likelihood that some strains such as Klebsiella oxytoca will compete with Salmonella for the remaining resources," says Osbelt-Block.

AbbVie (ABBV) announced the U.S. Food and Drug Administration approval of Emblaveo (aztreonam and avibactam). This marks the first ...

AbbVie (ABBV) announced that the U.S. Food and Drug Administration has approved EMBLAVEO, as the first and only fixed-dose, intravenous, ...

AbbVie receives US FDA approval for Emblaveo to treat adults with complicated intra-abdominal infections with limited or no treatment options: North Chicago, Illinois Monday, Febr ...

Blood cultures and cultures of the tip of a central venous catheter yielded Klebsiella oxytoca. Bullae formed ... infant was treated with broad-spectrum antibiotics, ventilation, diuretics ...

AbbVie has announced that the U.S. Food and Drug Administration (FDA) has approved EMBLAVEO (aztreonam and avibactam), as a ...